ArticleCureus2026
Depressive Symptoms in Patients With SARS-CoV-2 and Acute Coronary Syndrome.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2020, the World Health Organization (WHO) declared the outbreak of Coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Besides well-known pulmonary complications, other frequent detrimental health consequences included cardiovascular, thromboembolic, and mental health disorders. A high incidence of acute coronary syndromes (ACSs) with both short- and long-term outcomes was influenced by the disease severity and related complications, including mental health challenges, depression, and anxiety. The aim of our study was to analyze the prevalence of depressive symptoms (somatic and cognitive) in patients with SARS-CoV-2 infection and concomitant cardiovascular disease (CVD). Depression screening was conducted in 101 patients who survived SARS-CoV-2 infection during the 2020-2022 period. Of the study sample, 54 (53.5%) were female, and 47 (46.5%) were male, with the mean age of 55 (15.9 SD) years. All participants completed the Beck Depression Inventory (BDI) one to three months after hospital discharge. Patients with SARS-CoV-2 and ACS demonstrated a higher frequency of depressive symptoms compared to COVID-19-only patients without ACS. Statistically significant differences were observed in somatic symptoms (sleeplessness, irritability, loss of appetite, difficulties in concentration, tiredness), as well as in cognitive symptoms (loneliness, sadness, crying, fatigue, self-hatred, loss of interests, devaluation, indecision, and agitation). Our study findings suggest that acute severe illness (SARS-CoV-2 and ACS), elderly age, and the presence of chronic diseases can contribute to depressive mood. These observations highlight the need for multidisciplinary care involving cardiologists, neurologists, psychiatrists, and rehabilitation specialists with a comprehensive assessment of depressive symptoms and consideration of classical risk factors, which can potentially affect prognosis. However, these findings should be interpreted as associative, given the cross-sectional design of the study and the presence of confounding factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.